RA0046

antibody from Oursmab

Targeting: C5 C5a, C5b, CPAMD4

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0046

Provider

Oursmab

Product name

Crovalimab (Biosimilar Reference Antibody) (C5)

Antibody type

Monoclonal

Description

Crovalimab is a novel, engineered anti-complement C5 monoclonal antibody developed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Marketed under the brand name PiaSky?, it is distinguished by its unique pH-dependent, recycling mechanism. This design allows for sustained complement inhibition with a significantly longer half-life, enabling convenient subcutaneous administration every four weeks, unlike the standard intravenous regimens of other C5 inhibitors. It provides an effective therapeutic option for PNH patients, including those who may have experienced breakthrough hemolysis on other C5 therapies.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Crovalimab (Biosimilar Reference Antibody) (C5)-RA0046-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Crovalimab (Biosimilar Reference Antibody) (C5)-RA0046 in a linear range of 3.91-125 ng/mL.